Companies › Sinfatin
1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Rimonabant Cannabinoid CB1 receptor antagonist | CNR1 | Phase 1 | Cervical Spinal Cord Injury | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07843108 | Rimonabant | Phase 1 | Cervical Spinal Cord Injury | Neurology | Aug 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.